Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.

Albisetti, Manuela; Schlosser, Arno; Brueckmann, Martina; Gropper, Savion; Glund, Stephan; Tartakovsky, Igor; Brandão, Leonardo R; Reilly, Paul A

Albisetti, Manuela; Schlosser, Arno; Brueckmann, Martina; Gropper, Savion; Glund, Stephan; Tartakovsky, Igor; Brandão, Leonardo R; Reilly, Paul A.

Afiliação

Albisetti M; Hematology Department University Children's Hospital Zurich Switzerland.
Schlosser A; Department of Clinical Development Boehringer Ingelheim bv Alkmaar the Netherlands.
Brueckmann M; Clinical Development and Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany.
Gropper S; Faculty of Medicine Mannheim University of Heidelberg Mannheim Germany.
Glund S; Clinical Development and Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany.
Tartakovsky I; Translational Medicine and Clinical Pharmacology Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany.
Brandão LR; Clinical Development and Medical Affairs Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany.
Reilly PA; Department of Pediatrics Division of Haematology/Oncology University of Toronto The Hospital for Sick Children Toronto ON Canada.

Res Pract Thromb Haemost ; 2(1): 69-76, 2018 Jan.

Article em En | MEDLINE | ID: mdl-30046708

Palavras-chave

children; dabigatran etexilate; idarucizumab; oral anticoagulants; venous thromboembolism

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Res Pract Thromb Haemost Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google